MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

Search

Recursion Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.49 -0.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.34

Max

5.69

Pagrindiniai rodikliai

By Trading Economics

Pajamos

31M

-172M

Pardavimai

4.4M

19M

Pelno marža

-899.843

Darbuotojai

800

EBITDA

44M

-148M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+7.79% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-405M

2.1B

Ankstesnė atidarymo kaina

5.85

Ankstesnė uždarymo kaina

5.49

Naujienos nuotaikos

By Acuity

50%

50%

152 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-03 14:47; UTC

Pagrindinės rinkos jėgos

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

2025-10-03 14:25; UTC

Pagrindinės rinkos jėgos

Shopify Shares Rise as TD Cowen Raises Price Target

2025-10-03 13:20; UTC

Įsigijimai, susijungimai, perėmimai

Anglo American Initiates Arbitration Proceedings After Peabody Deal Falls Through

2025-10-03 12:40; UTC

Pagrindinės rinkos jėgos

Alto Neuroscience Shares Rise After Getting FDA Fast-Track Designation

2025-10-03 22:02; UTC

Įsigijimai, susijungimai, perėmimai

First National Financial Gets Ontario Court Approval for Sale to Birch Hill Equity and Brookfield

2025-10-03 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-03 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-10-03 19:56; UTC

Rinkos pokalbiai

Treasury Yields Have Weekly Loss as Key Statistics Go Unseen -- Market Talk

2025-10-03 19:52; UTC

Įsigijimai, susijungimai, perėmimai

This Mini-Berkshire Insurer Looks Cheap After Sale Of California Unit At High Price -- Barrons.com

2025-10-03 19:21; UTC

Rinkos pokalbiai

Crude Prices End Week Lower Ahead of OPEC Meeting -- Market Talk

2025-10-03 19:05; UTC

Rinkos pokalbiai

Natural-Gas Futures Face Mild Temperatures -- Market Talk

2025-10-03 19:04; UTC

Įsigijimai, susijungimai, perėmimai

BlackRock Group Hunts a $20 billion Deal to Get In on the AI Boom -- WSJ

2025-10-03 18:22; UTC

Rinkos pokalbiai

Bank of Canada Tentative About More Rate Cuts Due to Upside CPI Risks -- Market Talk

2025-10-03 17:15; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Decreased Last Week -- Market Talk

2025-10-03 16:26; UTC

Rinkos pokalbiai

Long-Term Treasury Yields Expected to Shrug Off Fed Cut -- Market Talk

2025-10-03 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-10-03 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-03 16:16; UTC

Rinkos pokalbiai

Alaska Air, American Airlines Expected to Post Disappointing 3Q Results -- Market Talk

2025-10-03 16:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-03 16:02; UTC

Rinkos pokalbiai

Airline Industry Bifurcation Likely to Define 3Q Earnings -- Market Talk

2025-10-03 15:17; UTC

Įsigijimai, susijungimai, perėmimai

Tech Buyouts Have Heated Up. These 8 Companies Could Be Next. -- Barrons.com

2025-10-03 14:56; UTC

Rinkos pokalbiai

European Credit Spreads Could Tighten as New Supply Stays Low -- Market Talk

2025-10-03 14:10; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-03 14:10; UTC

Rinkos pokalbiai

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

2025-10-03 13:34; UTC

Rinkos pokalbiai

Natural Gas Futures Down Amid High Supply, Mild Demand -- Market Talk

2025-10-03 13:29; UTC

Rinkos pokalbiai

Crude Prices Rise Slightly Ahead of OPEC+ Meeting -- Market Talk

2025-10-03 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-03 13:14; UTC

Rinkos pokalbiai

Brazilian Companies Face Higher Financing Costs, Fitch Says -- Market Talk

2025-10-03 13:10; UTC

Rinkos pokalbiai

Bitcoin Looks Ripe For Fresh Record High -- Market Talk

2025-10-03 12:52; UTC

Rinkos pokalbiai

Ferrari Results Secondary to Investor Day -- Market Talk

Akcijų palyginimas

Kainos pokytis

Recursion Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

7.79% į viršų

12 mėnesių prognozė

Vidutinis 5.95 USD  7.79%

Aukščiausias 8 USD

Žemiausias 3 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Recursion Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.15 / 4.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

152 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat